BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone203-643-8060
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions
What is BioXcel Therapeutics' stock symbol?
BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."
How were BioXcel Therapeutics' earnings last quarter?
BioXcel Therapeutics Inc (NASDAQ:BTAI) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.54) EPS for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.02. View BioXcel Therapeutics' Earnings History.
When is BioXcel Therapeutics' next earnings date?
What price target have analysts set for BTAI?
3 brokerages have issued 1 year target prices for BioXcel Therapeutics' shares. Their predictions range from $21.00 to $25.00. On average, they anticipate BioXcel Therapeutics' stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 263.1% from the stock's current price. View Analyst Price Targets for BioXcel Therapeutics.
What is the consensus analysts' recommendation for BioXcel Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.
What are Wall Street analysts saying about BioXcel Therapeutics stock?
Here are some recent quotes from research analysts about BioXcel Therapeutics stock:
- 1. According to Zacks Investment Research, "BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. " (9/11/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We utilize a discounted cash flow (DCF)-based assessment, which yields a total rNPV of $335M for for BXCL701. We thus derive a total enterprise value of $455M, which translates into a price objective of $25.00 based on 18M fully-diluted shares outstanding as of end-3Q19." (1/4/2019)
Has BioXcel Therapeutics been receiving favorable news coverage?
Media headlines about BTAI stock have been trending negative on Monday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioXcel Therapeutics earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for BioXcel Therapeutics.
Are investors shorting BioXcel Therapeutics?
BioXcel Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 254,600 shares, an increase of 19.9% from the August 30th total of 212,400 shares. Based on an average trading volume of 56,900 shares, the days-to-cover ratio is presently 4.5 days. Approximately 3.8% of the shares of the stock are sold short. View BioXcel Therapeutics' Current Options Chain.
Who are some of BioXcel Therapeutics' key competitors?
Some companies that are related to BioXcel Therapeutics include Beyondspring (BYSI), Magenta Therapeutics (MGTA), Stemline Therapeutics (STML), Verrica Pharmaceuticals (VRCA), AMAG Pharmaceuticals (AMAG), Merus (MRUS), Avedro (AVDR), Syros Pharmaceuticals (SYRS), BioSpecifics Technologies (BSTC), Arcus Biosciences (RCUS), Kiniksa Pharmaceuticals (KNSA), Obseva (OBSV), XBiotech (XBIT), Lexicon Pharmaceuticals (LXRX) and ImmunoGen (IMGN).
What other stocks do shareholders of BioXcel Therapeutics own?
Who are BioXcel Therapeutics' key executives?
BioXcel Therapeutics' management team includes the folowing people:
- Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
- Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
- Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
- Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
- Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)
When did BioXcel Therapeutics IPO?
(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
Who are BioXcel Therapeutics' major shareholders?
BioXcel Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (7.57%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Institutional Ownership Trends for BioXcel Therapeutics.
Which institutional investors are buying BioXcel Therapeutics stock?
BTAI stock was bought by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Insider Buying and Selling for BioXcel Therapeutics.
How do I buy shares of BioXcel Therapeutics?
Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioXcel Therapeutics' stock price today?
One share of BTAI stock can currently be purchased for approximately $6.15.
How big of a company is BioXcel Therapeutics?
BioXcel Therapeutics has a market capitalization of $96.75 million. The company earns $-19,270,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.View Additional Information About BioXcel Therapeutics.
What is BioXcel Therapeutics' official website?
How can I contact BioXcel Therapeutics?
BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-643-8060 or via email at [email protected]
MarketBeat Community Rating for BioXcel Therapeutics (NASDAQ BTAI)
MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote "Outperform" if you believe BTAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
